NEW YORK (GenomeWeb News) – Atossa Genetics said after the close of the market on Thursday that its full-year 2013 revenues grew 31 percent year over year on increased product sales.

The Seattle-based firm recorded $632,558 in total revenues for 2013, up from $481,842 in 2012. While diagnostic testing service revenues slipped to $409,118 from $475,402, product sales rose to $223,440 from $6,440, Atossa said, noting that $205,590 in product sales resulted from the purchase of 10,000 ForeCYTE specimen collection kits by Millennium Healthcare.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.